Physician profile
Reshma Patel
NPI 1841818804
$1,058.44
in general payments reported to CMS, 2019-2025
17 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $285 · 2023: $236 · 2024: $140 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $216.40 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $148.39 | 2021-2022 | |
| Coopervision INC. | $124.82 | 2023-2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $101.25 | 2022-2025 | Acuvue |
| Rxsight INC | $78.95 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Vision LLC | $59.80 | 2022 | |
| Abbvie INC. | $52.95 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $46.94 | 2025 | Xdemvy |
| Genzyme Corporation | $45.00 | 2023 | |
| Biotissue Holdings INC. | $41.82 | 2025 | |
| Dompe US, INC. | $31.27 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $21.00 | 2021 | |
| Horizon Therapeutics Plc | $20.81 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.69 | 2021 | |
| Oyster Point Pharma, INC. | $18.45 | 2023 | Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.07 | 2021 | |
| Aerie Pharmaceuticals, INC. | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.